Guanabenz—an old drug with a potential to decrease obesity

• Published in: Naunyn-Schmiedeberg's archives of pharmacology Vol. 395; no. 8; pp. 963 - 974
• Main Authors: Kotańska, Magdalena, Knutelska, Joanna, Nicosia, Noemi, Mika, Kamil, Szafarz, Małgorzata
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2022; Springer Nature B.V
• Subjects: Adipose tissue; Biomedical and Life Sciences; Biomedicine; Body weight; Dyslipidemia; Gastric emptying; High fat diet; Hyperglycemia; Metabolic syndrome; Metabolism; Neurosciences; Obesity; Original; Original Article; Pharmacology/Toxicology; Phenols; Risk factors; Rodents; Gastric emptying; Metabolic syndrome; Core temperature; Body weight; Guanabenz
• ISSN: 0028-1298; 1432-1912
• DOI: 10.1007/s00210-022-02251-1

The aim of this study was to determine, in the diet-induced obesity model in rats, the potential of Guanabenz to reduce body weight and ameliorate some metabolic disturbances. Obesity was induced in rats by a high-fat diet. After 10 weeks, rats were treated intraperitoneally with Guanabenz at the two doses: 2 or 5 mg/kg b.w./day, once daily for 25 days. The spontaneous activity of rats was measured for 24 h on the 1st and 24th day of the Guanabenz treatment with a special radio-frequency identification system. Gastric emptying was measured in intragastric phenol red-treated mice by measuring the color of the stomach homogenate 30 min after phenol red administration. Intraperitoneal administration of Guanabenz for 25 days to obese rats resulted in a significant decrease in body weight compared to the baseline values (about 11% at a dose of 5 mg/kg). Both body weight and the amount of adipose tissue in the groups receiving Guanabenz decreased to the levels observed in the control rats fed only standard feed. The anorectic effect occurred in parallel with a reduction in plasma triglyceride levels. We also confirmed the beneficial effect of Guanabenz on plasma glucose level. The present study demonstrates that the administration of Guanabenz strongly inhibits gastric emptying (about 80% at a dose of 5 mg/kg). Guanabenz can successfully and simultaneously attenuate all the disorders and risk factors of metabolic syndrome: hypertension, hyperglycemia, obesity, and dyslipidemia. However, the exact cellular mechanisms of its action require further research.